ClinicalTrials.gg
TerminatedNCT01066468Updated Mar 13, 2012

Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.

A Phase 1 interventional study of Gleevec/Glivec in Chronic Myeloid Leukemia (CML), Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) and Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN), sponsored by Novartis Pharmaceuticals. Terminated at 1 site in Russian Federation. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2012-03-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
1 Year to 3 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Enrollment
80th of 83
3 · median 60
Started
2010
with 1 other
Phase 1
12 of 93
none open now
Registered
66th of 93
by date
Lead sponsor
15 of 93
Novartis Pharmaceuticals

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 80th largest by enrollment of the 83 interventional ones that give a count, is one of 2 that started in 2010, is one of 12 in phase 1, and was the 66th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 1 Year to 3 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to \<4 years of age to help develop dosing regimens

03

Conditions studied

  • Chronic Myeloid Leukemia (CML)
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
  • Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)

Keywords

  • Chronic myeloid leukemia
  • CML
  • Philadelphia chromosome positive
  • acute lymphoblastic leukemia
  • PhGlivec,
  • Gleevec,
  • hypereosinophilic syndrome,
  • HES,
  • chronic eosinophilic leukemia,
  • CEL,
  • myelodysplastic syndrome,
  • MDS,
  • myeloproliferative disease,
  • MPD+ ALL
04

Who can participate

Ages eligible
1 Year to 3 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must be 1 to less than 4 years of age at study entry
  2. Written must be signed by the patient's parent or legal guardian.
  3. Patients must have the diagnosis of CML or Ph+ ALL
  4. Lansky score must be ≥ 50 (Table7-2)
  5. Patient must have adequate end organ function as defined by

    • Total \< 1.5 x
    • (ALT) and SGOT (AST) \< 2.5 x UNL
    • Creatinine \< 1.5 x ULN

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received drugs a) known to be metabolized by or 3A5, b) are CYP inhibitors and inducers, within 2 weeks prior to Visit 2 (except for imatinib)
  2. Patients who previously received radiotherapy to ≥ 25% of the bone marrow, with the exception of patients who received total body radiation as part of a preparatory regimen for hematopoetic stem cell transplant ()
  3. Patients receiving antibacterial and antipyretic medication to treat active infection
  4. Patients with (INR) or partial thromboplastin time (PTT) > 1.5 x , with the exception of patients on treatment with oral anticoagulants
  5. Patients whose parents or legal guardians, in the opinion of the Investigator, were unlikely to comply with the protocol or safety monitoring requirements

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Gleevec/Glivec

    Drug: Gleevec/Glivec

Interventions

  • DrugGleevec/Glivec

    Drug page: Imatinib

    Also known as: STI571

06

What researchers measure

Primary outcomes

  1. Measure: Pharmacokinetic data o (CL/F (clearance) o V/F (Volume of distribution) o Tmax o Physiologically based pharmacokinetic (PBPK) parameters (plasma protein binding and α-1 acid glycoprotein concentration)

    Time frame: 2 PK sample collection within 21 days

Secondary outcomes

  1. safety and tolerability of imatinib during the study period

    Time frame: study period of 21 days

07

Study locations

1 site
  • Novartis Investigative Site
    Moscow, 117997, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010 and a primary completion of May 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2010
First posted
Feb 10, 2010
Start
Oct 2010
Primary completionActual
May 2011
Last update
Mar 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01066468
Responsible party
Sponsor
First posted
Feb 10, 2010
Start date
Oct 2010
Primary completion
May 2011
Last update
Mar 13, 2012

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion